Key takeaways
- A dermatologist checks the pattern before treating it. Fungal infection, traction, patterned loss and scarring alopecia need different treatment. AAD
- The AAD describes observation for one or two patches present for less than a year; more extensive disease may need local treatment, contact immunotherapy or systemic assessment. AAD
- Oral JAK inhibitors help some people with severe alopecia areata. Infection, blood-count, liver, heart, cancer and clot risks still require individual screening and monitoring. HSA
Alopecia areata treatment depends on extent, age and disease activity
The British Association of Dermatologists describes regrowth starting with fine white hairs in the centre of a patch. They may thicken and regain colour. The hair roots have not been permanently lost in alopecia areata, so regrowth is possible, although its timing and durability are uncertain.
This immune-mediated, non-scarring condition can affect a recent scalp patch, most of the scalp or body hair. Extent, duration, age, continuing activity, eyebrows and eyelashes, previous regrowth and personal priorities all influence treatment. Systemic treatment needs monitoring and cannot promise permanent regrowth.
How is alopecia areata distinguished from other hair loss?
Examination usually starts with the bald areas and the nails. Alopecia areata often appears suddenly as smooth, round or oval patches. The short hairs at an active edge may taper into the shape called an “exclamation mark”. Loss can also affect beard, eyebrow, eyelash or body hair. The British leaflet compares the small pits in affected nails to the dimples of a thimble; nails may become brittle too.
In the AAD diagnostic guide, the examination includes a dermatoscope for magnification and questions about blood relatives with alopecia areata. The British leaflet puts family history at about 2 in 10 affected people. Blood tests for thyroid disease, iron or vitamin levels may be useful in selected cases. Sometimes a few hairs are removed for examination or a small skin biopsy is needed. Testing is not automatic.
According to the British Association of Dermatologists leaflet, a typical patch has no scale, although some people have diffuse loss. Scaling and broken hairs suggest another possibility, scalp fungal infection. A receding edge may be due to traction; a widening part may be patterned loss. Shiny skin, pain, pustules or missing follicular openings raise the possibility of scarring. Those conditions need different treatment.
Why might a recent patch be observed rather than treated?
Hair can regrow on its own in a small, recent patch. The AAD’s example is one or two bald spots that have been there for less than a year. Many people, particularly children, have regrowth without medicine. With a secure diagnosis, you can discuss observation if you are comfortable waiting. Keep track of spread, new patches, nail changes and daily-life effects for review.
Regrowth can take months and, rarely, years, according to the British leaflet. It is less predictable after extensive loss, and further episodes are common. An initially small patch can spread; regrowth does not establish a cure. Immediate systemic treatment for every patch would expose people to risk they may not need to take.
What treatment categories may be discussed?
The options depend on the extent and sites involved, rather than a fixed treatment ladder. The AAD describes corticosteroid injections for selected adults with patchy loss, usually at visits 4 to 6 weeks apart. In a study of 127 patients it summarises, more than 80% of those treated with injections had at least half their hair regrow within 12 weeks. That finding concerns patchy disease; it is not a result to assume for widespread loss.
| Situation | Treatment discussion may include | Main limitation or monitoring question |
|---|---|---|
| A few limited patches | Observation; topical or injected corticosteroid in selected patients | Local skin effects, discomfort with injections and uncertain durability |
| More extensive scalp loss | Contact immunotherapy delivered by a specialist service; selected systemic medicines | Repeated visits, deliberate dermatitis with contact therapy, systemic adverse effects |
| Severe or extensive disease | An oral JAK inhibitor for an eligible age and severity group | Infection and laboratory screening, medicine interactions and class safety warnings |
| Eyebrow or eyelash involvement | Site-specific local options, camouflage or systemic-treatment assessment | Eye-area safety and whether wider disease justifies systemic exposure |
| Children | Age-appropriate observation or local treatment; selected systemic options for eligible older children | Pain, age licensing, school impact and long-term safety evidence |
Corticosteroids suppress inflammation locally or systemically. With contact immunotherapy, a specialist deliberately produces a controlled allergic dermatitis. The AAD describes weekly visits after initial sensitisation, with the chemical left on covered skin for 48 hours and a rash expected to last about 36 hours. This is a supervised procedure, with repeated appointments and skin reactions to consider.
Minoxidil may help retain regrowth, without treating the autoimmune cause. Spironolactone and finasteride are used in discussions of other hair-loss patterns; their appearance in a hair catalogue is not a reason to add them to an alopecia-areata plan.
What changes when a JAK inhibitor is considered?
Systemic immune treatment requires an assessment of benefit and risk. JAK inhibitors interrupt immune signalling. The AAD JAK-inhibitor guide describes US approvals for baricitinib and deuruxolitinib in adults, and ritlecitinib from age 12, for severe or extensive alopecia areata. Local registration and availability need a separate check.
The guide reports that after about 6 months of ritlecitinib, 23% of trial participants had at least 80% scalp-hair coverage and 13.4% had at least 90% coverage. These are measures of coverage, not a promise of universal or permanent regrowth, and they do not rank the medicines against each other.
HSA’s safety alert, dated 13 December 2022, explains the background to major cardiovascular event, cancer, thrombosis and mortality warnings. The ORAL Surveillance study enrolled 4,362 people with rheumatoid arthritis, aged 50 or older with at least one additional cardiovascular risk factor. It compared tofacitinib with TNF inhibitors. HSA considered that other JAK inhibitors used for inflammatory conditions might share these risks.
HSA’s December 2022 assessment kept a positive benefit-risk conclusion for approved indications, where Singapore use was already second-line or later. It asked prescribers to pay particular attention to older people, current and former smokers, and cardiovascular, cancer or clot risk factors. The British leaflet also discusses serious infection in the JAK safety warnings. These risks still need assessment even when hair regrowth is the reason for treatment.
Assessment before and during treatment may cover infections, vaccinations, tuberculosis or viral-hepatitis risk, blood counts, liver function, lipids, pregnancy, smoking, clot and cardiovascular history, cancer and interacting medicines. The product information and individual plan determine the exact checks.
How should treatment success be judged?
Measure regrowth, what remains and any new loss in a consistent way. Use photographs with similar lighting and the same measure of scalp involvement. Daily mirror checks are harder to compare. In the ritlecitinib example, coverage was assessed at about 6 months; that is not a measure of permanent recovery. Discuss eyebrow, eyelash and nail changes, side effects, distress and the burden of visits at the review too.
The AAD describes tiny nail dents, brittle nails and crumbling, with some children’s nail changes improving on their own. Tell the clinician if these bother you. Eyelash loss can leave eyes dry and sore in wind, according to the British leaflet. The AAD suggests glasses for protection and describes artificial lashes as a camouflage option; it advises removing artificial lashes before bed to reduce irritation and further loss.
The AAD describes wigs and hairpieces for people waiting for regrowth, avoiding side effects or continuing to lose hair despite treatment. A scalp prosthesis is its term for a custom-fitted wig. Eyebrow options, peer support and psychological care are also valid choices. You may value partial regrowth, or decide that the result does not justify the burden. Camouflage and support are parts of care, not evidence of failure.
What changes the answer?
A recent patch and longstanding widespread loss have different prospects for regrowth. Check new patches, changes at their edges, rapid spread and nail involvement when reviewing disease activity and urgency.
Young children, adolescents and adults have different tolerability and authorised options. Pregnancy or plans for pregnancy affect systemic immunomodulators and some local treatments. Infection history, other immune conditions, cardiovascular or clot risks, cancer and smoking need review before systemic treatment.
Measured scalp area does not capture everything. Eyebrow loss, visibility, work, school, culture and distress can make a small area important. The British leaflet reports higher rates of depression and anxiety in affected people in a UK study and encourages discussion of emotional and social effects.
When should the diagnosis or plan be reviewed promptly?
Have rapid loss or signs of another scalp disorder assessed. Arrange review for widespread loss, eyebrow or eyelash loss, nail changes, pain, pus, marked scale, a shiny scar-like surface, loss after a new medicine or uncertainty about the pattern.
During systemic treatment, seek prompt advice for fever, significant infection, unexplained bruising, chest pain, sudden breathlessness, one-sided leg swelling or another serious new symptom. The alopecia-areata page and hair-loss category explain terms and ingredients; they cannot diagnose immune-mediated loss or select systemic treatment.
Sources
- American Academy of Dermatology: Alopecia areata: diagnosis and treatment.
- British Association of Dermatologists: Alopecia areata patient information.
- American Academy of Dermatology: JAK inhibitors: what patients should know.
- Singapore Health Sciences Authority: JAK inhibitors and serious safety risks.
